OXUR.BR实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 21:18):

Stats
今日成交量	126.76M
平均成交量	104.90M
市值	738 439
EPS	€0 ( 2024-04-05 )
Last Dividend	€0 ( N/A )
Next Dividend	€0 ( N/A )
P/E	0
ATR14	€0 (0.00%)

Oxurion NV 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Oxurion NV 财务报表

Annual	2023
营收:	€263 000
毛利润:	€104 000 (39.54 %)
EPS:	€-0.0115

FY	2023
营收:	€263 000
毛利润:	€104 000 (39.54 %)
EPS:	€-0.0115

FY	2022
营收:	€595 000
毛利润:	€-271 000 (-45.55 %)
EPS:	€-0.370

FY	2021
营收:	€1.13M
毛利润:	€516 000 (45.74 %)
EPS:	€-0.928

Financial Reports:

No articles found.

Oxurion NV

Oxurion NV, a biopharmaceutical company, develops and commercializes medicines for the treatment of eye diseases in Belgium and internationally. Its lead product is JETREA for the treatment of vitreomacular adhesion/vitreomacular traction. The company also develops THR-149, a plasma kallikrein inhibitor, which is in Phase II clinical trials for the treatment of diabetic macular edema (DME); and THR-687, an integrin antagonist which is in Phase II clinical trials for the treatment of DME. It has collaboration agreements with Bicycle Therapeutics, INC Research, and Galapagos NV. The company was formerly known as ThromboGenics NV and changed its name to Oxurion NV in September 2018. Oxurion NV was founded in 1991 and is headquartered in Leuven, Belgium.